6623-43-4

Usage

Uses

Used in Pharmaceutical Industry:
2-(1-phenylethylamino)ethanol is used as a precursor in the synthesis of various pharmaceutical drugs, specifically for the production of sympathomimetic amines and adrenergic agonists. Its adrenergic properties make it a valuable component in the development of medications that stimulate the sympathetic nervous system.
Used in Chemical Industry:
In the chemical industry, 2-(1-phenylethylamino)ethanol is utilized in the production of surfactants and emulsifiers. Its amphiphilic nature allows it to reduce the surface tension between different substances, making it an effective ingredient in these products.
Used in Personal Care Industry:
2-(1-phenylethylamino)ethanol is also used in the formulation of personal care products, such as perfumes and fragrances. Its unique properties contribute to the stability and effectiveness of these products.
Due to its potential stimulant effects, it is crucial to handle 2-(1-phenylethylamino)ethanol with care and to use it in accordance with appropriate safety protocols to ensure the safety of both users and the environment.

InChI:InChI=1/C10H15NO/c1-9(11-7-8-12)10-5-3-2-4-6-10/h2-6,9,11-12H,7-8H2,1H3

Upstream product

• 141-43-5 ethanolamine 
• 98-86-2 acetophenone 
• 693-06-1 (2-hydroxyethyl)-formamide 
• 64-17-5 ethanol 
• 618-36-0 rac-methylbenzylamine 
• 540-51-2 2-bromoethanol 
• 65687-97-0 2-methyl-2-phenyloxazolidine 
• 164219-31-2 ethyl (S)-2-oxo-2-((1-phenylethyl)amino)acetate 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 107-07-3 2-chloro-ethanol 
• 164219-32-3 (S)-2-oxo-2-((1-phenylethyl)amino)acetic acid 
• 75-21-8 oxirane 
• 2627-86-3 (-)-α-methylbenzylamine 

Downstream Products

• 102881-92-5 N-(2-hydroxy-ethyl)-N-(1-phenyl-ethyl)-β-alanine nitrile 
• 103206-32-2 (1-phenyl-ethyl)-(2-vinyloxy-ethyl)-carbamic acid methyl ester 
• 6948-01-2 N-formyl-α-methylbenzylamine 
• 618-36-0 rac-methylbenzylamine 
• 1420476-88-5 7-bromo-2-(1-phenylethyl)-3,4-dihydro-1H-pyrido[1,2-a]pyrazine-1,6(2H)-dione 
• 1420476-96-5 2-(1-phenylethyl)-3,4-dihydro-1H-pyrido[1,2-a]pyrazine-1,6(2H)-dione 
• 1616921-73-3 6-((1-(4-chlorophenyl)cyclopentyl)methyl)-9-hydroxy-2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-c]pyrimidine-1,8(2H)-dione 
• 1616922-95-2 5-(benzyloxy)-N-(2-(tert-butyldimethylsilyloxy)ethyl)-2-((1-(4-chlorophenyl)cyclopentyl)methyl)-6-hydroxy-N-(1-phenylethyl)pyrimidine-4-carboxamide 
• 1616922-96-3 5-(benzyloxy)-2-((1-(4-chlorophenyl)cyclopentyl)methyl)-6-hydroxy-N-(2-hydroxyethyl)-N-(1-phenylethyl)pyrimidine-4-carboxamide 
• 1616922-97-4 9-(benzyloxy)-6-((1-(4-chlorophenyl)cyclopentyl)methyl)-2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-c]pyrimidine-1,8(2H)-dione 
• 1616922-94-1 2-(tert-butyldimethylsilyloxy)-N-(1-phenylethyl)ethanamine 
• 100596-36-9 hydrobromide (-)-N-(2-bromzethyl)-α-phenylethylamine 
• 207690-58-2 ((S)-1-Phenyl-ethyl)-(2-triisopropylsilanyloxy-ethyl)-amine 
• 817168-33-5 4-((S)-1-Phenyl-ethyl)-morpholine-2,3-dione 

Relevant academic research and scientific papers

Synthesis of pyrrole N-derivatives from oxazolidines

Transformations of oxazolidine derivatives synthesized from industrially produced amino alcohols, aldehydes, and ketones under basic or acidic catalysis lead to the formation of N-alkyl- and N-(hydroxyalkyl)-substituted pyrroles in 19-81% yields.

PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Chemodivergent synthesis of 7-aryl/alkyl-6-hydroxy-1,4-oxazepan-5-ones and 2-[aryl/alkyl(hydroxy)methyl]morpholin-3-ones from a common epoxyamide precursor

We present here a regiospecific synthesis of 7-alkyl- or 7-aryl-6-hydroxy-1,4-oxazepan-5-ones and 2-[aryl(hydroxy)methyl]- or 2-(1-hydroxyalkyl)morpholin-3-ones from a diastereomeric mixture of trans-3-alkyl- or -3-aryl-N-(2-hydroxyethyl)-N-(1-phenylethyl)oxirane-2- carboxamides. This chemodivergent synthesis is easily controlled by an appropriate choice of cyclization reaction conditions. Georg Thieme Verlag Stuttgart - New York.

Efficient preparation of secondary aminoalcohols through a Ti(IV) reductive amination procedure. Application to the synthesis and antibacterial evaluation of new 3β-N-[hydroxyalkyl]aminosteroid derivatives

An efficient method for the synthesis of various secondary aminoalcohols through a titanium(IV) isopropoxide-mediated reductive amination reaction of ketones is reported. Thus, different ketones gave the expected products in moderate to excellent yields up to 89% in numerous cases. A series of 3β-N-[hydroxyalkyl]aminosteroid derivatives were prepared according to this methodology and evaluated for their in vitro antimicrobial properties against human pathogens. All the compounds showed moderate to excellent activities against Gram-positive bacteria exhibiting similar results against Staphylococcus aureus and Streptococcus faecalis with Minimum Inhibitory Concentrations (MICs) varying from 3.12 to 25 μg/mL. No significant antibacterial activities are encountered against Gram-negative bacteria.

Practical asymmetric preparation of azetidine-2-carboxylic acid

Facile and straightforward syntheses of both enantiomers of azetidine-2-carboxylic acid are described. The syntheses depart from inexpensive chemicals and allow for the production, in five to six steps, of practical quantities of each enantiomer. Synthetic highlights include the construction of the azetidine ring using an intramolecular alkylation and the use of optically active α-methylbenzylamine as chiral auxiliary.

Syntheses of morpholine-2,3-diones and 2-hydroxymorpholin-3-ones: Intermediates in the synthesis of aprepitant

The preparation of morpholine-2,3-diones and 2-hydroxymorpholin-3-ones from N-substituted β-amino alcohols is reported. These were useful intermediates in the synthesis and development of aprepitant.

Selective Access to Secondary Amines by a Highly Controlled Reductive Mono-N-Alkylation of Primary Amines

A selective and direct access to secondary amines is reported by reductive mono-N-alkylation of primary amines in the presence of Ti(i-PrO)4 and NaBH4. Secondary amines are obtained exclusively from a set of carbonyl compounds and primary amines, demonstrating high chemoselectivity toward reductive mono-N-alkylation.

Structural studies on bioactive compounds. 34.1 Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase

The triazenyl-pyrimethamine derivative 3a (TAB), a potent and selective inhibitor of Pneumocystis carinii DHFR, was selected as the starting point for a lead optimization study. Molecular modeling studies, corroborated by a recent crystal structure determination of the ternary complex of P. carinii DHFR-NADPH bound to TAB, predicted that modifications to the acetoxy residue of the lead inhibitor could exploit binding opportunities in the vicinity of an active site pocket bounded by residues Ile33, Lys37, and Leu72. Substitutions in the benzyl moiety with electron-donating and electron-withdrawing groups were predicted to probe face-edge interactions with amino acid Phe69 unique to the P. carinii enzyme. New triazenes 10a-v and 12a-f were prepared by coupling the diazonium tetrafluoroborate salt 6b of aminopyrimethamine with substituted benzylamines or phenethylamines. The most potent of the new inhibitors against P. carinii DHFR was the naphthylmethyl-substituted triazene 10t (IC50: 0.053 μM), but a more substantial increase in potency against the rat liver DHFR led to a reduction in selectivity (ratio rat liver DHFR IC50/P. carinii DHFR IC50: 5.36) compared to the original lead structure 3a (ratio rat liver DHFR IC50/P. carinii DHFR IC50: 114).

Process for preparation of pyrimidine derivatives

The present invention relates to a process for preparation of 5,6-dimethyl-2-(4-fluorophenyl-amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine represented by the following formula (I), STR1 and its acid addition salts by reacting a pyrimidi

The Use of Heterocycles for the Conformational Restriction of Biologically Active Peptoids

A series of piperazinone ring systems have been synthesized as a means of evaluating the effect of conformational restriction of high affinity non-peptide NK1, NK3 and CCK-B receptor ligands.The synthesis of the targeted heterocycles is described along with a discussion of their affinities for their respective receptor types.